Compare KFS & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KFS | EOLS |
|---|---|---|
| Founded | 1989 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.8M | 304.0M |
| IPO Year | 1996 | 2018 |
| Metric | KFS | EOLS |
|---|---|---|
| Price | $12.23 | $4.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.40 |
| AVG Volume (30 Days) | 74.5K | ★ 1.1M |
| Earning Date | 03-16-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $128,567,000.00 | ★ $285,823,000.00 |
| Revenue This Year | N/A | $13.70 |
| Revenue Next Year | N/A | $13.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.31 | 15.10 |
| 52 Week Low | $7.06 | $4.09 |
| 52 Week High | $16.80 | $17.12 |
| Indicator | KFS | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 34.61 | 32.43 |
| Support Level | $13.18 | $4.09 |
| Resistance Level | $13.27 | $4.61 |
| Average True Range (ATR) | 0.42 | 0.27 |
| MACD | -0.11 | 0.02 |
| Stochastic Oscillator | 1.28 | 23.22 |
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.